Skip to content
Homepage
Author:
Liminatus Pharma Inc.
Posted Date:
June 30, 2026
Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline
Liminatus Pharma Inc.
June 30, 2026
Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds
Liminatus Pharma Inc.
June 3, 2026
Liminatus Pharma Announces Nasdaq Delisting Notification
Liminatus Pharma Inc.
May 21, 2026
Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline
Liminatus Pharma Inc.
May 21, 2026
Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody
Liminatus Pharma Inc.
March 17, 2026
